Opus Genetics Completes Dosing in Cohort 2 of OPGx-BEST1 Trial
Opus Genetics completed dosing in Cohort 2 of its Phase 1/2 clinical trial of OPGx-BEST1 gene therapy for inherited retinal diseases.
Story updates
12:05:18 PM UTC
SquawkNews
The higher-dose Cohort 2 in the BIRD-1 study enrolled 11 patients, above the original target of five